Respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) remain the third leading cause of death globally and are growing in prevalence throughout the world. According to the World Health Organization (WHO), COPD affects 251 million people and was the cause of death for 3.17 million people, reflecting 5% of all deaths worldwide. In their Millennium Development Goals (MDG), the WHO urges that through cooperation with pharmaceutical companies, developing countries can provide access to affordable, essential drugs. Frédérique Bordes-Picard and Sven Stegemann of Lonza Pharma and Biotech expand on this possibility.
[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/05/Inhalation-advances.pdf” width=”100%” height=”900px” style=”border:0;”]